Background: Cerebrospinal fluid amyloid-β 1-42 (Aβ42) is an important biomarker for Alzheimer’s disease, both in diagnostics and to monitor disease-modifying therapies. However, there is a great need for harmonization of methods used for quantification. To overcome problems associated with immunoassays, mass spectrometry (MS) has emerged as a critical alternative.
Methods: We compared results for CSF Aβ42 quantification in a Round Robin study, performed in four laboratories using similar sample preparation methods and triple quadrupole MS instrumentation.
Results: The MS results showed excellent correlation between laboratories (R2 > 0.98), high analytical precision, and good correlation with ELISA (R2 > 0.85). The use of a common reference sample further decreased inter-laboratory variation.
Conclusions: Our results indicate that MS is suitable for absolute quantification of Aβ42 in CSF and highlights the importance of developing a certified reference material.
PANNEE Josef;
GOBOM Johan;
SHAW Leslie;
KORECKA Magdalena;
CHAMBERS Erin;
LAME Mary;
JENKINS Rand;
MYLOTT William;
CARRILLO Maria;
ZEGERS Ingrid;
ZETTERBERG Henrik;
BLENNOW Kaj;
PORTELIUS Erik;
2016-01-21
ELSEVIER SCIENCE INC
JRC89435
1552-5260,
10.1016/j.jalz.2015.06.1890,
https://publications.jrc.ec.europa.eu/repository/handle/JRC89435,
| Name | Country | City | Type |
|---|
This document is only visible at the Commission level.
You are not authorized to publish or distribute it outside the European Commission.
This is a public document. You can share this publication.
Datasets
| ID | Title | Public URL |
|---|
Dataset collections
| ID | Acronym | Title | Public URL |
|---|
Scripts / source codes
| Description | Public URL |
|---|
Additional supporting files
| File name | Description | File type |
|---|